(Q33578490)

28 July 2017

1 reference

title

Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease (English)

1 reference

28 July 2017

1 reference

coronary artery disease

1 reference

Goa KL

1

1 reference

28 July 2017

Barradell LB

series ordinal

2

1 reference

28 July 2017

McTavish D

series ordinal

3

1 reference

28 July 2017

publication date

1 January 1997

1 reference

28 July 2017

1 reference

28 July 2017

volume

11

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

89-110

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

28 July 2017

cites work

1 reference

12 December 2020

Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia

1 reference

12 December 2020

Screening for hypercholesterolemia among Canadians: how much will it cost?

1 reference

12 December 2020

What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.

1 reference

12 December 2020

Cost-effectiveness of combined statin-resin therapy

1 reference

12 December 2020

Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

12 December 2020

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

1 reference

12 December 2020

Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. American College of Physicians. Part 1

1 reference

12 December 2020

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group

1 reference

12 December 2020

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

1 reference

12 December 2020

Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden

1 reference

12 December 2020

A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease.

1 reference

12 December 2020

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Fluvastatin cost considerations

1 reference

12 December 2020

Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria

1 reference

12 December 2020

Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cholesterol-lowering therapy: is there really a controversy?

1 reference

12 December 2020

Cost-effectiveness of accepted measures for intervention in coronary heart disease.

1 reference

12 December 2020

Costs and cost effectiveness of health checks conducted by nurses in primary care: the Oxcheck study

1 reference

12 December 2020

Cholesterol lowering, low cholesterol, and mortality

1 reference

12 December 2020

Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants

1 reference

12 December 2020

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

1 reference

12 December 2020

Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands

1 reference

12 December 2020

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

1 reference

12 December 2020

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

12 December 2020

The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care

1 reference

12 December 2020

Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

The 4S study and its pharmacoeconomic implications

1 reference

12 December 2020

Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin

1 reference

12 December 2020

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors.

1 reference

12 December 2020

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1 reference

12 December 2020

Selection of end points in economic evaluations of coronary-heart-disease interventions

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Cholesterol screening in asymptomatic adults, revisited. Part 2.

1 reference

12 December 2020

Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease

1 reference

12 December 2020

Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease

1 reference

12 December 2020

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

12 December 2020

Cholesterol-lowering intervention program. Effect of the step I diet in community office practices

1 reference

12 December 2020

Serum cholesterol concentration and death from suicide in men: Paris prospective study I.

1 reference

12 December 2020

Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt

1 reference

12 December 2020

Cost of prevention. The case of lipid lowering

1 reference

12 December 2020

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study

1 reference

12 December 2020

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

1 reference

12 December 2020

Benefits and costs of medical nutrition therapy by registered dietitians for patients with hypercholesterolemia. Massachusetts Dietetic Association

1 reference

12 December 2020

The economics of cholesterol lowering

1 reference

12 December 2020

Lipid intervention trials in primary prevention: a critical review

1 reference

12 December 2020

The costs and effects of two different lipid intervention programmes in primary health care

1 reference

12 December 2020

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

12 December 2020

Management of hypercholesterolemia

1 reference

12 December 2020

Pharmacoeconomic evaluation of risk factors for cardiovascular disease: an epidemiological perspective

1 reference

12 December 2020

Strategies for reducing coronary risk factors in primary care: which is most cost effective?

1 reference

12 December 2020

One year experience in the treatment of familial hypercholesterolaemia with simvastatin

1 reference

12 December 2020

Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.

1 reference

12 December 2020

Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study.

1 reference

12 December 2020

Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients

1 reference

12 December 2020

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study

1 reference

12 December 2020

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Cost of coronary heart disease in New Zealand.

1 reference

12 December 2020

Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation to published recommendations

1 reference

12 December 2020

A review of clinical trials comparing HMG-CoA reductase inhibitors

1 reference

12 December 2020

Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine

1 reference

12 December 2020

A model for evaluating the cost-effectiveness of cholesterol-lowering treatment

1 reference

12 December 2020

Cost-effectiveness of hypolipidaemic drugs

1 reference

12 December 2020

The cholesterol controversy

1 reference

12 December 2020

Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia

1 reference

12 December 2020

Cholesterol-lowering diets. A review of the evidence

1 reference

12 December 2020

1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand

1 reference

12 December 2020

Evidence-based management of dyslipidaemia

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Changes in total serum cholesterol and other risk factors for cardiovascular disease in Japan 1980-1989.

1 reference

12 December 2020

Cholesterol agonistics

1 reference

12 December 2020

Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine

1 reference

12 December 2020

Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1 reference

12 December 2020

Pharmaco-economic assessment of the HMG-CoA reductase inhibitors

1 reference

12 December 2020

Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association

1 reference

12 December 2020

Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

1 reference

12 December 2020

Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants

1 reference

12 December 2020

Dose-response of simvastatin in primary hypercholesterolemia

1 reference

12 December 2020

10.2165/00019053-199711010-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1000246674

0 references

1 reference